Document is current
Any future updates will be listed below
-
Authors
Rejeski, Kai https://orcid.org/0000-0003-3905-0251
Hill, Joshua A. https://orcid.org/0000-0002-7665-7100
Dahiya, Saurabh
Jain, Michael D. https://orcid.org/0000-0002-7789-1257
- License Information
-
More Information
Article History
Received: 14 November 2024
Accepted: 4 June 2025
First Online: 16 July 2025
Competing interests
: K.R.: Kite/Gilead: research funding, consultancy, honoraria and travel support; Novartis: honoraria; BMS/Celgene: consultancy, honoraria; Pierre-Fabre: travel support. J.A.H.: research funding: Allovir, Geovax, Takeda and Gilead; consultancy: Allovir, CSL Behring, Geovax, Karius, Gilead and Moderna. S.D.: research funding: Kite Pharma/Gilead, Novartis and Kyverna Therapeutics; advisory board/consulting: Kite Pharmaceuticals/Gilead Pharma, Bristol Myers Squibb, Incyte, Adaptive Biotechnologies. M.D.J.: Kite/Gilead: consultancy/advisory, research funding; Novartis: consultancy/advisory; Incyte: research funding; Lilly: research funding. None of these competing interests were related to the financing of this study.
